Data cannot be shared publicly because of protected health information. Data are available from the respective center Institutional Data Access / Ethics Committee (contact via email) for researchers who meet the criteria for access to confidential data. Please contact<RSPAdmin@roswellpark.org> regarding the head and neck database under EDR-103707.

Introduction {#sec005}
============

Head and Neck cancers of unknown primary origin represent a disease in which regional spread of disease is detected when the primary site is not able to be determined after diagnostic work up \[[@pone.0231042.ref001]\]. Unknown primaries of the head and neck represent approximately 3% of all head and neck cancers, with the majority being squamous cell carcinoma \[[@pone.0231042.ref001],[@pone.0231042.ref002]\]. The diagnostic work up for these patients typically includes a fine needle aspiration followed by clinical exam of the most likely locations for the primary tumor \[[@pone.0231042.ref002]\]. If clinical exam fails to identify a primary tumor, imaging studies and close physical examination, often including direct laryngoscopy with or without "blind" biopsies \[[@pone.0231042.ref003]\], are used to identify the site. The use of positron emission tomography (PET) scans in diagnostic work up has significantly improved identification of primary tumors, nodal involvement, and has narrowed the population of patients with unknown primary tumors of the head and neck \[[@pone.0231042.ref004],[@pone.0231042.ref005]\]. However even in the PET era, there remains a subset of patients where a primary tumor cannot be identified.

Current treatment options for unknown primaries of the head and neck remain controversial and include surgery, concurrent chemoradiation (CCRT), radiation alone (RT), or surgery followed by CCRT or RT \[[@pone.0231042.ref002]\]. In patients treated with radiotherapy, the volume of treatment is debated. Specifically, it is unclear whether to use unilateral radiation therapy (radiation to one side of the head and neck, usually covering the ipsilateral tonsil and base of tongue) versus comprehensive radiation therapy (radiation therapy to all likely mucosal sites and both sides of the head and neck). One prospective study evaluating the use of unilateral vs. bilateral radiation therapy opened in 2002 and unfortunately was closed due to low accrual rates \[[@pone.0231042.ref002]\]. The majority of retrospective studies which attempt to address the question of unilateral versus bilateral irradiation include patients treated before the advent of PET scans \[[@pone.0231042.ref005]\] or newer radiation techniques, such as Intensity Modulated Radiation Therapy (IMRT) \[[@pone.0231042.ref002]\]. Many of the patients in these earlier investigations may have had their primary identified and/or better characterized bilateral neck involvement by modern imaging and as such, it is unclear how well they represent a contemporary cohort. For example, former pre-PET unknown primary carcinoma of the head and neck patients often had occult oropharyngeal squamous cell carcinoma, in which unilateral radiation therapy is often safe and recommended. \[[@pone.0231042.ref004],[@pone.0231042.ref005]\] Therefore, further investigation is needed regarding treatment volumes within the PET era.

The goal of this study was to evaluate the effects of radiation treatment volume on recurrence and mortality among head and neck cancer patients who underwent PET imaging with unknown primaries and were treated at two different cancer centers.

Materials and methods {#sec006}
=====================

Clinical characteristics of 62 patients with unknown primaries of the head and neck treated from 2000--2015 at two academic medical centers were abstracted from the medical records. All patients had confirmed squamous cell carcinoma. Patients either received radiation therapy to one side of the head and neck (unilateral radiation), or radiation therapy to both sides of the head and neck (bilateral radiation) ([Table 1](#pone.0231042.t001){ref-type="table"}). In the event of concern for bilateral neck involvement, irradiation to both necks would be an absolute indication regardless of treating center. However, in other instances inclusion of the elective contralateral neck was at the discretion of the treating physician.

10.1371/journal.pone.0231042.t001

###### Treatment volumes, modalities, and concurrent therapy.

![](pone.0231042.t001){#pone.0231042.t001g}

                                Center A     Center B   
  ----------------------------- ------------ ---------- ----
  **RT volume**                 Unilateral   28         6
  Bilateral                     5            23         
  **RT technique**              IMRT         22         18
  3DCRT                         11           11         
  **Concurrent chemotherapy**   Cisplatin    30         13
  Cetuximab                     3            3          
  Other                         0            3          
  None                          0            10         
  **Surgery**                   Yes          12         6
  No                            21           23         

All 33 patients treated at Center A received routine PET scan and direct examination in the operating room. All were treated with concurrent radiation therapy (CCRT). Of these, 30 received cisplatin based therapy and 3 were treated with cetuximab. Induction chemotherapy was given prior to CCRT in 4 patients. Twelve patients received a neck dissection either prior to or after CCRT. IMRT was used in 22 patients. The radiation volume always encompassed the ipsilateral oropharynx (base of tongue, tonsil) and level 1B to V lymph nodes. If clinical exam or imaging (including PET) revealed evidence concerning for bilateral neck involvement then both necks, bilateral 1B to V lymph nodes were treated along with the bilateral oropharynx (base of tongue, tonsil). IMRT dosing (70 Gy to gross tumor and oropharynx with 56 Gy to the nodes at risk in 35 fractions) and technique has been previously described \[[@pone.0231042.ref006],[@pone.0231042.ref007]\]. 3DCRT was delivered to 70 Gy in 35 fractions to the ipsilateral oropharynx and positive nodes and 50 Gy to the supraclavicular region in 25 fractions.

Patients treated at Center B received routine PET scan and direct examination in the operating room (n = 29). RT was delivered with either three dimensional conformal radiation therapy (3DCRT) (11 patients) or IMRT (18 patients). Target volume delineation and prescription dose was at the discretion of the treating physician based on patient and tumor factors. Sixteen and five patients underwent neck dissection prior to, and after, radiotherapy, respectively. Two patients were treated to the neck without mucosal site irradiation. Three patients were treated only to the oropharynx, 8 patients were treated to oropharynx and nasopharynx, and 15 patients were treated to the orpharynx, nasopharynx, hypopharynx and larynx. Detailed information regarding RT targets was not available in two patients. Nineteen patients received concurrent chemotherapy, consisting of cisplatin in 13, cetuximab in 3, and a combination or other in 3. Median dose to gross disease or highest risk area (assuming neck dissection) was 66 Gy. Median dose to uninvolved but high risk areas was 59.7 Gy (26 patients). Unilateral elective treatment was used in 4 patients, while the rest received bilateral treatment.

Statistical analysis {#sec007}
--------------------

Mann Whitney U tests for ordinal data and Chi square and Fischer exact tests for categorical data were conducted to compare demographic and outcome factors between patients treated unilaterally and patients treated bilaterally. Overall survival (OS) and disease free survival (DFS) trends for unilaterally and bilaterally treated patients were estimated using Kaplan-Meier survival curves. The effect of treatment volume on overall survival and disease free survival were examined using multivariate cox proportional hazard regression models. Models were adjusted for age and nodal stage. A p-value of \< 0.05 was considered statistically significant. All analyses were performed using SAS version 9.4

Results {#sec008}
=======

The majority of patients were white (88.71%), male (74.19%), and former smokers (54.84%). There were no significant differences in age (p = 0.13), sex (p = 0.65), smoking status (p = 0.17), or N stage (p = 0.61) between patients treated unilaterally and patients treated bilaterally ([Table 2](#pone.0231042.t002){ref-type="table"}).

10.1371/journal.pone.0231042.t002

###### Characteristics of unilaterally and bilaterally treated patients with squamous cell carcinoma of the head and neck from an unknown primary (n = 62).

![](pone.0231042.t002){#pone.0231042.t002g}

  Characteristic                                                    Bilateral Treatment (n = 28) Median (range) or N (%)   Unilateral Treatment (n = 34) Median (range) or N (%)   [\*](#t002fn001){ref-type="table-fn"}p-value
  ----------------------------------------------------------------- ------------------------------------------------------ ------------------------------------------------------- ----------------------------------------------
  **Age (years)**                                                   57.00 (41--82)                                         60.72 (44.65--75.00)                                    0.13
  **Sex**                                                                                                                                                                          
      Male                                                          20 (71.43)                                             26 (76.47)                                              
      Female                                                        8 (28.57)                                              8 (23.53)                                               0.65
  **Smoking Status**                                                                                                                                                               
      Never                                                         4 (14.29)                                              12 (35.29)                                              
      Former                                                        18 (64.29)                                             16 (47.06)                                              
      Current                                                       6 (21.43)                                              6 (17.65)                                               0.17
  **Nodal stage**                                                                                                                                                                  
      Nodal stage1                                                  4 (14.29)                                              7 (20.59)                                               
      Nodal stage 2                                                 15 (53.57)                                             20 (57.14)                                              
      Nodal stage3                                                  9 (32.14)                                              7 (20.59)                                               0.61
  [^¶^](#t002fn002){ref-type="table-fn"}**Local Failure**                                                                                                                          
      No                                                            25 (89.29)                                             33 (97.06)                                              
      Yes                                                           3 (10.71)                                              1 (2.94)                                                0.32
  [^**\^**^](#t002fn003){ref-type="table-fn"}**Regional Failure**                                                                                                                  
      No                                                            28 (100.00)                                            32 (94.12)                                              
      Yes                                                           0 (0.00)                                               2 (5.88)                                                0.50
  [^**ע**^](#t002fn004){ref-type="table-fn"}**Distant Failure**                                                                                                                    
      No                                                            22 (78.57)                                             28 (82.35)                                              
      Yes                                                           6 (21.43)                                              6 (17.65)                                               0.76
  **Current Status**                                                                                                                                                               
      Alive                                                         18 (64.29)                                             23 (67.65)                                              
      Dead                                                          10 (35.71)                                             11 (32.35)                                              0.78
  **Disease Status** (excludes deceased)                                                                                                                                           
                                                                                                                                                                                   
      No evidence of disease                                        18 (100.00)                                            20 (86.96)                                              
      Alive with this HN cancer                                     0                                                      1 (4.35)                                                0.50
      Alive with other cancer                                       0                                                      2 (8.70)                                                

\*Mann Whitney U tests conducted for ordinal data; Chi square or Fisher Exact test conducted for categorical data

^¶^Local Failure = same site

^\^^Regional Failure = within head neck/surrounding lymph nodes

^ע^Distant Failure = metastasis anywhere else in body

No significant differences in the frequency of local (p = 0.32), regional (p = 0.50), or distant (p = 0.76) failures were observed between patients treated unilaterally and those treated bilaterally ([Table 2](#pone.0231042.t002){ref-type="table"}). Moreover, Kaplan-Meier estimates for OS (3-year OS bilateral = 71.67%, unilateral = 77.90%, p = 0.50, [Fig 1](#pone.0231042.g001){ref-type="fig"}) and DFS (3-year DFS bilateral = 77.92%, unilateral = 69.43%, p = 0.63, [Fig 2](#pone.0231042.g002){ref-type="fig"}) were similar between the two treatment approaches. Furthermore, there was no statistically significant effect of treatment volume on disease free survival in both univariate (HR = 0.77, 95% CI: 0.28, 2.18, p = 0.63) and multivariate (HR: 0.68, 95% CI: 0.24, 1.93, p = 0.47) analyses ([Table 3](#pone.0231042.t003){ref-type="table"}).

![Kaplan-Meier three-year overall survival of unilaterally (77.90%) and bilaterally (71.67%) treated patients with squamous cell carcinoma of the head and neck with unknown primary (p = 0.50).](pone.0231042.g001){#pone.0231042.g001}

![Kaplan Meier three-year disease free survival of unilaterally (69.43%) and bilaterally (77.92%) treated patients with squamous cell carcinoma of the head and neck from an unknown primary (p = 0.63).](pone.0231042.g002){#pone.0231042.g002}

10.1371/journal.pone.0231042.t003

###### Cox proportional hazard ratio models for overall and disease free survival in patients with squamous cell carcinoma of the head and neck from an unknown primary (n = 62).

![](pone.0231042.t003){#pone.0231042.t003g}

  Model                                                   Overall Survival    Disease Specific Survival                       
  ------------------------------------------------------- ------------------- --------------------------- ------------------- -------
  **Univariate**                                                                                                              
      Unilateral                                          1.00                                            1.00                
      Bilateral                                           0.74 (0.30, 1.80)   0.504                       0.77 (0.28, 2.18)   0.627
  **Age adjusted**                                                                                                            
      Unilateral                                          1.00                                            1.00                
      Bilateral                                           0.82 (0.34, 2.00)   0.661                       0.83 (0.29, 2.23)   0.725
  [\*](#t003fn002){ref-type="table-fn"}**Multivariate**                                                                       
      Unilateral                                          1.00                                            1.00                
      Bilateral                                           0.74 (0.31, 1.81)   0.511                       0.68 (0.24, 1.93)   0.465

Abbreviations: HR, hazard ratio; 95% CI, 95% confidence interval

\*Multivariate model adjusted for age and nodal stage

Discussion {#sec009}
==========

The current study evaluates the approach of two different centers in the management of unknown primary of the head and neck. In this cohort, Center B favored bilateral neck irradiation whereas Center A preferred unilateral coverage. As there were no significant association between nodal stage and radiation volumes, it is likely this difference is driven by preference of the prescribing physician and not by concern for bilateral neck involvement. This study found no significant difference in three year OS or DFS between patients treated with unilateral or bilateral head and neck radiotherapy. In addition, there was no significant difference in rates of local, regional, or distant failures among the treatment groups. Ligey et al \[[@pone.0231042.ref008]\] also observed no significant difference in tumor control or overall survival between patients treated unilaterally or bilaterally. Similarly, Le at el. reported no oncologic benefit to bilateral neck irradiation as well.\[[@pone.0231042.ref009]\] Our results are consistent with other published reports \[[@pone.0231042.ref010]--[@pone.0231042.ref013]\].

While other reports have suggested that bilateral neck radiotherapy may result in improvements in local tumor control and overall survival \[[@pone.0231042.ref014]--[@pone.0231042.ref017]\], these studies were conducted in an era prior to the more widespread use of PET imaging. A recent meta-analysis of 16 studies concluded that bilateral radiation therapy provided better local and regional control than unilateral radiation therapy \[[@pone.0231042.ref018]\]. In addition, although not statistically significant, there were trends towards improved overall survival in the bilaterally treated patient population \[[@pone.0231042.ref018]\]. However, these studies include patient populations from the 1970s to the early 2000s, with the majority of the patients having been treated before the widespread adoption of PET imaging. Even the most recent of these papers, Beldi et al \[[@pone.0231042.ref019]\] includes a population of patients that ranges from 1998--2004. The majority of patients included in these studies would not have been treated with IMRT\[[@pone.0231042.ref020]\], but with 2D and 3D radiation therapy.

The studies by Ligey et al (2009) \[[@pone.0231042.ref008]\], Perkins et al (2012)\[[@pone.0231042.ref010]\], Lu et al (2009)\[[@pone.0231042.ref011]\], McMahon et al (2000)\[[@pone.0231042.ref012]\], Fakhrian et al (2012)\[[@pone.0231042.ref013]\], and Le et al. (2019)\[[@pone.0231042.ref009]\] which show similar outcomes regardless of volume irradiated, also include patients treated in prior decades, but had a higher proportion of patients treated in the mid-late 2000s. In addition to more advanced radiation therapy techniques \[[@pone.0231042.ref019]\], patients treated in more recent years had the benefit of undergoing PET scanning. With the advent of PET scanning, what would have been considered an unknown primary in past decades is now identified \[[@pone.0231042.ref002],[@pone.0231042.ref004],[@pone.0231042.ref005]\]. This technological innovation narrows the population of patients to true unknown primaries in the modern era and may explain the difference in survival outcomes between older and newer studies.

Local, regional, and distant failures were observed in both treatment groups with no statistically significant differences. The majority of the failures in both groups were at distant sites. Perkins et al (2012) \[[@pone.0231042.ref010]\] also found equal rates of distant metastasis between the two groups. Distant metastasis is the most common site of failure for unknown primary tumors and represents a substantial risk to a patient's overall survival \[[@pone.0231042.ref002]\]. As rates of distant metastasis in this study and others do not appear to be altered by unilateral radiation therapy, the benefits of unilateral radiation therapy may be achieved with no significant difference in survival.

The benefits of unilateral radiation therapy over bilateral radiation therapy include decreased toxicity and potentially improved quality of life. Although the results from Reddy et al (1997) \[[@pone.0231042.ref015]\] did not favor unilateral radiation therapy, they did observe more mucositis and xerostomia in patients treated with bilateral radiation therapy compared to patients treated with unilateral radiation therapy. Fakhrian et al (2012) \[[@pone.0231042.ref013]\] also observed more mucositis and xerostomia in bilaterally treated patients than unilaterally treated patients. There were no incidences of severe xerostomia in the unilateral patient group, compared to 4 incidences of severe xerostomia in the bilaterally treated group \[[@pone.0231042.ref013]\]. Le et al. (2019)\[[@pone.0231042.ref009]\] reported significantly worse acute dysphagia and mucositis with bilateral neck irradiation, with trends for increased acute laryngeal alteration and xerostomia as well \[[@pone.0231042.ref009]\]. Formerly, quality of life was not routinely measured making it difficult to assess. Future studies focusing on the beneficial effects of unilateral radiation therapy on quality of life are warranted. In addition to potential quality of life benefits, there is potential for a lower risk of toxicity in the unilateral population should a contralateral recurrence emerge.

This study represents one of the few studies to be conducted on a modern population of patients with squamous cell carcinoma of unknown primary origin of the head and neck. As a result, many of the patients in this study underwent PET imaging and were treated with intensity modulated radiation therapy. Furthermore, this paper is a multi-institutional study minimizing potential bias due to the treatment center.

Additionally, examining a modern population such as ours is likely to approximate the current incidence of human papilloma virus (HPV) infection which is known to impact incidence, epidemiology, and outcomes of head and neck cancer \[[@pone.0231042.ref021]\]. In this HPV era, there may even be differences in outcomes within different subsites of the oropharynx \[[@pone.0231042.ref022]\]. However, specific data on HPV are lacking in this cohort because most patients were diagnosed by fine needle aspiration (FNA) only and that p16 testing was not widely performed until after 2010. Despite a recent report on the technical feasibility of performing HPV on FNA specimens \[[@pone.0231042.ref023]\], this was not routine at the time and not done on our specimens.

The entrenched position of many physicians on how to treat unknown primary head and neck cancer has previously caused the aforementioned failure of a cooperative group trial on unilateral versus comprehensive mucosal irradiation. A recent review of the literature from October 2018 is one of the few papers to make recommendations on irradiation volume for unknown primaries.\[[@pone.0231042.ref024]\] They have recommended avoiding routine irradiation of all lymph node levels. Instead, they favor unilateral radiation for those with low risk N stages (N1, N2A, N2B) and consider bilateral irradiation for those with risk of contralateral metastases (N2C, N3).Furthermore, they found no survival benefit of bilateral radiation therapy accompanied by increased toxicity.\[[@pone.0231042.ref024]\] Of the three co-authors from center B of this publication, two of the co-authors now consider volume directed ipsilateral irradiation of the oropharynx and neck in the majority of patients and the third co-author expresses a hesitancy to change existing practice prior to a demonstration of diminished toxicity from unilateral therapy.

Conclusions {#sec010}
===========

Results of this study show that unilateral radiation therapy for unknown primaries of the head and neck does not have inferior overall survival, disease free survival, or increased rates of failures compared to bilateral radiation therapy. No significant differences in survival combined with the potential benefits of improved quality of life and decreased toxicity make unilateral radiation therapy an attractive prospect.

10.1371/journal.pone.0231042.r001
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Reviewer \#3: This study is the evaluation of recurrence and mortality according to the different radiation volume among head and neck cancer patients who underwent PET imaging with unknown primaries and were treated at two different cancer centers.

The authors concluded that that unilateral radiation therapy for unknown primaries of the head and neck does not have inferior overall survival, disease free survival, or increased rates of failures compared to bilateral radiation therapy. No significant differences in survival combined with the potential benefits of improved quality of life and decreased toxicity make unilateral radiation therapy an attractive prospect.

There is no description of the toxicity according to the different radiation therapy volume. Is there any analysis of the quality of life or side effects?

Thank you for this comment. This study did not include quality of life/toxicity as this data was not routinely collected at the participating centers during the study period however we have referenced and discussed previous studies which investigated these factors in lines 181-194.

Reviewer \#4: The authors present an interesting study to evaluate the whether unilateral or bilateral irradiation should be considered in head and neck cancer patients. From their analysis, they did not produce any conclusive or statistically significant results to conclude that one method should be used more than another. The work seems to be an underpowered and slightly unconvincing study without more patients or methods to assess toxicity. Nonetheless, it may be important to note that there were no significant differences between the two cases and that the unilateral case does not result in worse outcomes. The paper would be strengthened if the authors address the following issues:

\--The title of the paper remains too focused on unilateral irradiation when that is not necessarily warranted from their results. A more appropriate title should be given.

Thank you for this comment. We have changed the title to "Evaluation of radiation treatment volumes for unknown primaries of the head and neck in the era of FDG PET"

\--PET was still not appropriately introduced in the abstract as there was only a vague mention of the era of PET. There is no explanation as to why PET is important or what it can be used for. An additional sentence is necessary to make this connection.

Thank you for this suggestion. We have rewritten a portion of the abstract objectives seen on lines 29-32. "Positron-emission tomography (PET) has improved identification of the primary tumor as well as occult nodal burden in cancer of the head and neck. Nevertheless, there are still patients where the primary tumor cannot be located. In these situations, the standard of care is comprehensive head and neck radiation therapy however it is unclear whether this is necessary."

\--The unilateral vs. bilateral case mismatch in each center needs to be addressed and explained in 1st paragraph of the Materials and Methods section (e.g. why did most patients receive bilateral treatment in Center B? Was this due to evidence of bilateral neck involvement as in Center A?).

Thank you for this comment. This mismatch lies in approach of the treating physician, an approach that is grounded in philosophy rather randomized data given the lack of prospective trials examining this fairly rare clinical scenario. We had addressed what absolute indications for bilateral neck irradiation are in the text (lines 91-94). Furthermore, we have highlighted the fact there were no association between nodal stage and radiation volumes and clarified that the driving force between bilateral vs unilateral coverage was the decision to electively cover the contralateral neck in the absence of PET avid disease. (lines 143-147) This decision is largely a difference in treatment philosophy, which differed across the two centers. We then discuss how these data potentially impact this treatment approach of the involved physicians in lines 215-219.

\--The sentence starting on line 203 is misleading ("As in our study...accompanied by increased toxicity.") as the authors did not evaluate toxicity in their own study. This sentence should be updated to clarify this point.

Thank you for this comment. This has been addressed (line 215)
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Dear Dr. Singh,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <https://www.editorialmanager.com/pone/>, click the \"Update My Information\" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

With kind regards,

Jason Chia-Hsun Hsieh, M.D. Ph.D

Academic Editor
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The topic is well-presented and interesting in the head and neck cancer field. After revision, all the questions were addressed this time.
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I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

For any other questions or concerns, please email <plosone@plos.org>.
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